S-methyl 2-(1H-indole-3-carbonyl)thiazole-4-carbothioate | 1300545-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: S-methyl 2-(1H-indole-3-carbonyl)thiazole-4-carbothioate
• 英文别名: S-methyl 2-(1H-indole-3-carbonyl)-1,3-thiazole-4-carbothioate
• CAS: 1300545-09-8
• 化学式: C₁₄H₁₀N₂O₂S₂
• 分子量: 302.378
• InChiKey: WQZZLVYLALMJIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(1H-indole-3-carbonyl)thiazole-4-carboxylic acid 在 4-二甲氨基吡啶 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 S-methyl 2-(1H-indole-3-carbonyl)thiazole-4-carbothioate
  参考文献：
  名称：

  [EN] METHODS OF TREATING CANCER
  [FR] MÉTHODES DE TRAITEMENT DU CANCER

  摘要：

  本公开涉及使用免疫检查点蛋白抑制剂和吲哚化合物或其磷酸盐衍生物的组合来治疗患者的癌症方法。

  公开号：

  WO2020106695A1

文献信息

• ITE FOR CANCER INTERVENTION AND ERADICATION
  申请人：Ariagen, Inc.

  公开号：EP3689347A1

  公开（公告）日：2020-08-05

  A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.

  本发明公开了一种癌症干预或根除方法，即给癌症患者服用有效量的芳基烃（Ah）受体（AhR）内源配体 ITE 或其类似物之一（活性成分）。活性成分的有效剂量和给药频率是通过测量给药后受试者的血药浓度确定的。与载体系统配制的活性成分可局部、肠道或胃肠道给药。配制好的药物还可以与一种或多种其他癌症治疗药物一起使用。受试者痊愈后，还需继续用药，以确保根除癌症。前列腺癌、肝癌、肺癌、卵巢癌和乳腺癌患者最好接受治疗。
• ITE for cancer intervention and eradication
  申请人：Ariagen, Inc.

  公开号：US10195182B2

  公开（公告）日：2019-02-05

  A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.

  本发明公开了一种癌症干预或根除方法，即给癌症患者服用有效量的芳基烃（Ah）受体（AhR）内源配体 ITE 或其类似物之一（活性成分）。活性成分的有效剂量和给药频率是通过测量给药后受试者的血药浓度确定的。与载体系统配制的活性成分可局部、肠道或胃肠道给药。配制好的药物还可以与一种或多种其他癌症治疗药物一起使用。受试者痊愈后，还需继续用药，以确保根除癌症。前列腺癌、肝癌、肺癌、卵巢癌和乳腺癌患者最好接受治疗。
• Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
  申请人：Ariagen, Inc.

  公开号：US10632106B2

  公开（公告）日：2020-04-28

  Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

  本文提供的癌症治疗方法是给癌症患者施用有效量的芳基烃（Ah）受体（AhR）内源配体 ITE 或其结构类似物之一，例如前列腺癌、肝癌、肺癌、卵巢癌、乳腺癌、皮肤癌、结肠癌（或直肠癌）、胃癌、胰腺癌、肾癌、膀胱癌、软组织癌或宫颈癌。
• Indole compounds and their use
  申请人：ARIAGEN, INC.

  公开号：US11459322B2

  公开（公告）日：2022-10-04

  The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.

  本公开涉及吲哚化合物及其药物组合物，以及它们在刺激有需要的患者的免疫系统和治疗癌症方面的用途。
• WO2019/99977
  申请人：——

  公开号：——

  公开（公告）日：——